Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.
DitchCarbon Score
How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Swedish Orphan Biovitrum's score of 38 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Swedish Orphan Biovitrum's reported carbon emissions
In 2023, Swedish Orphan Biovitrum AB (Sobi) reported total carbon emissions of approximately 1551000 kg CO2e. This figure includes 904000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 648000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity, heat, and cooling. Notably, Scope 3 emissions were significantly higher, amounting to approximately 124565000 kg CO2e, which includes emissions from the supply chain and other indirect sources. Sobi has set ambitious near-term targets to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 37.8% by the fiscal year 2029, using 2023 as the baseline year. Additionally, the company aims for 65% of its suppliers, based on spend, to have science-based targets by the same year. These commitments align with industry standards for climate action and demonstrate Sobi's dedication to reducing its carbon footprint in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 435,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 1,157,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 1,031,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Swedish Orphan Biovitrum is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
